BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23529583)

  • 21. Bloodstream infections among children with juvenile idiopathic arthritis: a prospective study from the onset of disease.
    Salonen PH; Säilä H; Salonen JH; Vuorela M; Kautiainen H; Lyytikäinen O; Kauppi MJ; Leirisalo-Repo M; Repo H
    Clin Exp Rheumatol; 2014; 32(6):979-83. PubMed ID: 25436839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Infectious events during the first year of treatment with an antagonist of the tumor necrosis factor].
    Gulín Dávila J; González-Gay MA
    Farm Hosp; 2013; 37(5):351-7. PubMed ID: 24128096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort.
    Chhabra A; Oen K; Huber AM; Shiff NJ; Boire G; Benseler SM; Berard RA; Scuccimarri R; Feldman BM; Lim LSH; Barsalou J; Bruns A; Cabral DA; Chédeville G; Ellsworth J; Houghton K; Lang B; Morishita K; Rumsey DG; Rosenberg AM; Tse SM; Watanabe Duffy K; Duffy CM; Guzman J;
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):897-906. PubMed ID: 31074591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
    Beukelman T; Haynes K; Curtis JR; Xie F; Chen L; Bemrich-Stolz CJ; Delzell E; Saag KG; Solomon DH; Lewis JD;
    Arthritis Rheum; 2012 Apr; 64(4):1263-71. PubMed ID: 22328538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower genital tract infections in young female juvenile idiopathic arthritis patients.
    Ferreira GRV; Tomioka RB; Queiroz LB; Kozu K; Aikawa NE; Sallum AME; Serafini P; Tacla M; Baracat EC; Pereira RMR; Bonfá E; Silva CA
    Adv Rheumatol; 2019 Nov; 59(1):50. PubMed ID: 31730499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids.
    Vivarelli M; D'Urbano LE; Insalaco A; Lunt M; Jury F; Tozzi AE; Ravelli A; Martini A; Donn R; De Benedetti F
    Clin Exp Rheumatol; 2007; 25(5):775-81. PubMed ID: 18078632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
    Donnithorne KJ; Cron RQ; Beukelman T
    J Rheumatol; 2011 Dec; 38(12):2675-81. PubMed ID: 22089470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience].
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Reumatismo; 2007; 59(3):244-61. PubMed ID: 17898886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.
    Kimura Y; Grevich S; Beukelman T; Morgan E; Nigrovic PA; Mieszkalski K; Graham TB; Ibarra M; Ilowite N; Klein-Gitelman M; Onel K; Prahalad S; Punaro M; Ringold S; Toib D; Van Mater H; Weiss JE; Weiss PF; Schanberg LE;
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):23. PubMed ID: 28399931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections and antibiotics during fetal life and childhood and their relationship to juvenile idiopathic arthritis: a prospective cohort study.
    Kindgren E; Ludvigsson J
    Pediatr Rheumatol Online J; 2021 Sep; 19(1):145. PubMed ID: 34530851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden.
    Berthold E; Månsson B; Kahn R
    Arthritis Res Ther; 2019 Oct; 21(1):218. PubMed ID: 31661011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
    Shenoi S; Wallace CA
    Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Etiology of Juvenile Idiopathic Arthritis.
    Rigante D; Bosco A; Esposito S
    Clin Rev Allergy Immunol; 2015 Oct; 49(2):253-61. PubMed ID: 25384710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Clin Immunol; 2020 Feb; 211():108322. PubMed ID: 31830532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can quantitative MRI be used in the clinical setting to quantify the impact of intra-articular glucocorticoid injection on synovial disease activity in juvenile idiopathic arthritis?
    Bennett JL; Wood A; Smith N; Mistry R; Allen K; Jandial S; Tuckett JD; Gowdy SC; Foster HE; McErlane F; Hollingsworth KG
    Pediatr Rheumatol Online J; 2019 Nov; 17(1):74. PubMed ID: 31752877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
    Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.